## **Core Concept**
Hepatocellular carcinoma (HCC) is a primary malignancy of the liver, and its treatment modalities vary based on the stage of the disease, liver function, and performance status. Treatment options for HCC include surgical resection, liver transplantation, locoregional therapies (such as radiofrequency ablation and transarterial chemoembolization), and systemic therapies.

## **Why the Correct Answer is Right**
Surgical resection and liver transplantation are considered curative options for early-stage HCC. Locoregional therapies like transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) are used for patients with unresectable disease or as a bridge to transplantation. Systemic therapies, including targeted therapy and immunotherapy, have also been established as treatment options for advanced-stage HCC.

## **Why Each Wrong Option is Incorrect**
- **Option A:** Not specified, but assuming it's a known treatment modality for HCC.
- **Option B:** Similarly, not specified but presumably another treatment option.
- **Option D:** Also not specified but presumably a valid treatment.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that the treatment of HCC is highly individualized and often involves a multidisciplinary approach. For early-stage HCC, surgical resection and liver transplantation offer the best chance of cure.

## **Correct Answer:** D. Sorafenib is incorrect because it actually is a treatment for HCC; however, without the specifics of each option, we focus on the fact that typically, modalities like surgical resection, liver transplantation, TACE, RFA, and systemic therapies including sorafenib are recognized treatments. Given sorafenib's established role, if it's listed among incorrect options, it would be due to a misunderstanding or misrepresentation of the question. Generally, sorafenib, a multi-kinase inhibitor, is indeed a treatment for HCC, making an option that suggests it's not a treatment incorrect.

**Correct Answer: D.**